Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Alexion Pharmaceuticals fell $2.09 (-2.3%) to $90.21 on heavy volume. Throughout the day, 3.1 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in price between $89.81-$92.43 after having opened the day at $92.34 as compared to the previous trading day's close of $92.30. Other companies within the Drugs industry that declined today were: Celsion Corporation ( CLSN), down 10.4%, Apricus Biosciences ( APRI), down 9.7%, Pernix Therapeutics Holdings ( PTX), down 9.5%, and Rexahn Pharmaceuticals ( RNN), down 8.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $18.2 billion and is part of the health care sector. The company has a P/E ratio of 82.9, above the S&P 500 P/E ratio of 17.7. Shares are down 0.1% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Atossa Genetics ( ATOS), up 25.2%, StemCells ( STEM), up 21%, ZIOPHARM Oncology ( ZIOP), up 17.5%, and Albany Molecular Research ( AMRI), up 15.7%, were all gainers within the drugs industry with Teva Pharmaceutical Industries ( TEVA) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash